WHO Pharmaceuticals Newsletter No.5, 2014

3 de noviembre  2014

Tabla de contenidos

Regulatory Matters

Bupropion ....................................................................................... 4

Diclofenac ...................................................................................... 4

Methylphenidate .............................................................................. 5

Omalizumab ................................................................................... 5

Topiramate ..................................................................................... 5

Valproate ....................................................................................... 6

Safety of Medicines

Azathioprine ................................................................................... 7

Bo Ying Compound ® ....................................................................... 7

Bromocriptine ................................................................................. 7

Denosumab .................................................................................... 8

Ferumoxytol ................................................................................... 8

Measles, Mumps, Rubella, Varicella vaccine (MMRV) ........................... 8

Nitrofurantoin ................................................................................. 9

Zolpidem ........................................................................................ 9

Signal

Febuxostat and Cardiac Failure ........................................................ 11

Pamidronic acid and Optic Neuritis ................................................... 18

Fingolimod and Twave Inversion...................................................... 21

Feature

Eleventh Meeting of the WHO Advisory Committee on Safety of Medicinal

Products (ACSoMP)...................................................................... 27

 

Disponible en http://bit.ly/1x31WaS